Daily Ards Research Analysis
Analyzed 4 papers and selected 3 impactful papers.
Summary
A multicenter phase 1b/2 RCT suggests anti-C5a antibody STSA-1002 is safe and may shorten time to clinical improvement in viral pneumonia-related ARDS. A translational study identifies OGDH as an immunometabolic regulator driving M1-like polarization and ferroptosis in sepsis-associated lung injury, with inhibition via CPI-613 conferring protection through Nrf2. A post hoc PROSEVA analysis shows baseline respiratory system elastance and prone-induced driving pressure changes do not predict mortality benefit from prone positioning.
Research Themes
- Complement C5a inhibition in viral pneumonia-related ARDS
- Immunometabolism and ferroptosis in sepsis-associated lung injury
- Precision use of prone positioning: elastance and driving pressure
Selected Articles
1. Anti-C5a antibody STSA-1002 for patients with acute respiratory distress syndrome due to viral pneumonia: a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
In a multicenter phase 1b/2 randomized, double-blind, placebo-controlled trial of viral pneumonia-related ARDS (n=47 treated), anti-C5a antibody STSA-1002 showed a favorable safety profile. Time to clinical improvement was numerically shorter with 1350 mg (sHR 1.55; 95% CI 0.68–3.55) versus placebo, suggesting potential efficacy to be tested in phase 3.
Impact: This is a rigorously designed early-phase RCT targeting complement C5a in ARDS, providing human safety data and a potential efficacy signal for a mechanistically rational therapy.
Clinical Implications: No immediate practice change; results support enrollment in phase 3 trials and consideration of complement-targeted strategies for viral pneumonia-related ARDS.
Key Findings
- STSA-1002 demonstrated a favorable safety profile in viral pneumonia-related ARDS.
- Time to clinical improvement was 6.0 days (1350 mg), 8.4 days (750 mg), and 7.4 days (placebo).
- Competing risk analysis showed sHR 1.55 (95% CI 0.68–3.55) for 1350 mg and 1.04 (0.46–2.38) for 750 mg versus placebo, indicating a non-significant trend toward benefit at the higher dose.
Methodological Strengths
- Multicenter, randomized, double-blind, placebo-controlled design
- Appropriate competing risk model for time-to-clinical-improvement endpoint
Limitations
- Small sample size with wide confidence intervals crossing unity
- Early-phase trial focused on time-to-improvement rather than definitive mortality endpoints
Future Directions: Proceed to adequately powered phase 3 trials, consider biomarker-enriched designs (e.g., baseline complement activation) to identify responders, and evaluate effects on mortality and ventilator-free days.
BACKGROUND: ARDS constitutes a major cause of mortality with limited therapeutic options. RESEARCH QUESTIONS: Whether STSA-1002 is safe and clinically beneficial in ARDS due to viral pneumonia. STUDY DESIGN AND METHODS: We conducted a phase 1b/2, multi-center, double-blind, placebo-controlled trial. Participants aged between 18 and 85 years, suffering from ARDS due to viral pneumonia, with PaO RESULTS: Between December 9, 2023 and March 20, 2025, 49 patients were enrolled and randomized. Among the 47 patients who received study medication, 17 received STSA-1002 1350mg, 15 received STSA-1002 750mg, and 15 received placebo. The TTCI was 6.0 days in the STSA 1002 1350 mg group, 8.4 days in the STSA 1002 750 mg group and 7.4 days in the control group, with the sHR of 1.55 (95% CI, 0.68-3.55) for the STSA-1002 1350mg group and 1.04 (95% CI, 0.46-2.38) for STSA-1002 750mg group according to a competing risk model, both compared with the control group. After adjustment for the baseline PaO INTERPRETATION: STSA-1002 demonstrated a favorable safety profile and potential efficacy. These findings warrant confirmation in a phase 3 trial.
2. OGDH primes macrophage for M1-like polarization and ferroptosis in sepsis associated acute lung injury.
In LPS-induced sepsis models, OGDH activity increased while α-ketoglutarate decreased; pharmacologic inhibition with CPI-613 reduced acute lung injury, inflammation, and ferroptosis, improving survival. CPI-613’s anti-ferroptotic effects required Nrf2, and patient sera from sepsis-associated ARDS showed elevated OGDH activity correlating with severity and outcomes.
Impact: This study uncovers an immunometabolic mechanism linking OGDH to macrophage polarization and ferroptosis and provides multi-system validation, nominating OGDH activity as a biomarker and CPI-613 as a potential therapeutic strategy.
Clinical Implications: OGDH activity may serve as a biomarker for sepsis-associated ARDS severity; targeting OGDH with CPI-613 could be a therapeutic avenue, pending clinical trials.
Key Findings
- Sepsis increased OGDH enzyme activity and decreased α-ketoglutarate in mice.
- CPI-613 attenuated lung injury and systemic inflammation, improving survival in septic mice.
- CPI-613 suppressed M1-like polarization and ferroptosis and activated the Nrf2 antioxidant axis.
- Nrf2 silencing or inhibition abrogated CPI-613’s anti-ferroptotic effects; patient sera in sepsis-associated ARDS showed elevated OGDH activity correlated with severity and outcomes.
Methodological Strengths
- Integrated multi-omics with in vivo and in vitro validation
- Mechanistic confirmation using genetic (si-Nrf2) and pharmacologic (ML385) perturbations
Limitations
- LPS-induced sepsis model may not fully recapitulate human S-ALI pathophysiology
- Human validation is limited to serum enzyme activity correlations without detailed sample size
Future Directions: Prospective clinical studies to validate OGDH as a biomarker, test CPI-613 in early-phase ARDS/sepsis trials, and delineate cell-specific OGDH-Nrf2-ferroptosis signaling in human tissues.
BACKGROUND: Sepsis-associated acute lung injury (S-ALI) is a clinical syndrome characterized by dysregulated inflammation and overwhelming oxidative stress, and is associated with a poor prognosis. Alpha-ketoglutarate dehydrogenase (OGDH) is a key enzyme in the tricarboxylic acid cycle that catalyzes the oxidative decarboxylation of α-ketoglutarate (α-KG) to succinyl-CoA, a critical step linking mitochondrial energy metabolism to immune response. However, the mechanism by which OGDH participates in S-ALI remains unclear. METHODS: The mouse model of sepsis was established via intraperitoneal injection of lipopolysaccharide (LPS), and CPI-613 was administered intraperitoneally prior to LPS challenge. Peripheral blood samples and baseline characteristics were collected from septic patients. In vitro, BMDMs were used to evaluate the therapeutic effects of CPI-613. Using untargeted metabolomics (LC-MS), RNA sequencing transcriptomics (RNA-seq), macrophage-specific small interfering Nrf2 RNA (si-Nrf2), and enzyme-linked immunosorbent assay (ELISA), we assessed lung tissue pathology, inflammatory cytokine levels, ferroptosis markers, OGDH enzyme activity, and clinical correlation. RESULTS: In LPS-induced septic mice, we observed systemic metabolic changes characterized by decreased α-KG levels and increased OGDH enzyme activity. Intraperitoneal administration of the OGDH inhibitor CPI-613 attenuated acute lung injury and systemic inflammation, thereby improving survival. Flow cytometry revealed that CPI-613 suppressed M1-like polarization of alveolar macrophages in septic mice, a finding corroborated in vitro. Transcriptomic profiling indicated that CPI-613 treatment preferentially modulated ferroptosis and glutathione metabolic pathways in LPS-treated bone marrow-derived macrophages (BMDMs). In both LPS-challenged mice and BMDMs, CPI-613 reduced ferroptosis biomarkers and activated the Nrf2-mediated antioxidant axis. Critically, genetic silencing of Nrf2 via siRNA or pharmacological inhibition with ML385 eliminated the anti-ferroptotic effects of CPI-613, positioning Nrf2 as a central mediator of this protection. Serum from patients with sepsis-associated ARDS exhibited significantly elevated OGDH enzyme activity relative to healthy controls. Moreover, OGDH activity correlated strongly with disease severity and clinical outcomes, including septic shock and death. CONCLUSION: Overall, our study reveals that OGDH is a key immunometabolism regulator and a novel biomarker in S-ALI, and its inhibitor CPI-613 may represent a potential therapeutic target for this condition.
3. Elastance as a determinant of the effect of prone positioning on mortality in acute respiratory distress syndrome: a post hoc analysis of the PROSEVA trial.
In a Bayesian post hoc analysis of PROSEVA, baseline respiratory system elastance did not modify the mortality benefit of prone positioning. Although higher elastance correlated with greater early improvement in driving pressure, this physiologic response was not associated with reduced 90-day mortality.
Impact: Clarifies that elastance-based selection for prone positioning is unwarranted and cautions against using early driving pressure changes as a surrogate for mortality benefit.
Clinical Implications: Prone positioning should remain broadly applied in moderate-to-severe ARDS without stratifying by baseline elastance; improvements in driving pressure should not be assumed to translate into survival benefit.
Key Findings
- Baseline respiratory system elastance did not meaningfully modify the mortality effect of prone positioning (interaction OR 0.94; 90% CrI 0.74–1.20).
- Higher baseline elastance was associated with greater improvement in driving pressure after the first prone session (β = -3.3; 95% CI -4.09 to -2.49; p < 0.001).
- Prone-induced driving pressure reductions were not associated with mortality benefit in adjusted models (OR 1.14; 95% CI 0.96–1.37; p = 0.14).
Methodological Strengths
- Bayesian logistic regression with credible intervals to assess effect modification
- Use of randomized trial data set (PROSEVA) with predefined mortality endpoint
Limitations
- Post hoc analysis subject to residual confounding and multiple testing concerns
- Findings limited to passively ventilated ARDS patients within trial context
Future Directions: Prospective studies to identify robust predictors of prone responsiveness beyond elastance and to validate physiologic endpoints that map to survival.
BACKGROUND: Patient factors determining the benefit of prone positioning remain uncertain, resulting in the maneuver being applied indiscriminately among those with moderate-severe ARDS. We aimed to assess if baseline respiratory system elastance (Ers), or "stiffness", determines the treatment effect of prone positioning on mortality. METHODS: Bayesian logistic regression modeling of the PROSEVA Trial was used to estimate the posterior probability of prone positioning effect moderation by baseline Ers on 90-day mortality in patients with moderate-severe ARDS. As a secondary aim, we tested whether the absolute change in driving pressure of the respiratory system (∆DPrs ) in response to prone positioning predicted 90-day mortality, using logistic regression. RESULTS: The treatment effect of prone positioning on mortality did not meaningfully vary with baseline Ers (posterior probability of benefit OR < 0.95 = 52%; interaction OR 0.94, 90% credible interval, CrI, 0.74-1.20). Higher baseline Ers was associated with greater improvements in DPrs at the end of the first prone session (β= -3.3, 95% confidence interval (CI) -4.09, -2.49; p = < 0.001). However, this response was not associated with mortality benefit in adjusted models (OR 1.14, 95% CI 0.96, 1.37; p = 0.14). CONCLUSIONS: The effect of prone positioning on mortality did not vary with Ers in the PROSEVA trial. Similarly, prone positioning-induced improvement in DPrs was not predictive of mortality in this cohort of passively ventilated ARDS patients.